Abstract
BackgroundMultiple cancer immunotherapies of T-cell checkpoint inhibitors have been approved worldwide. However, most patients with advanced solid tumors do not benefit, or relapse after T-cell checkpoint blockade. Myeloid checkpoint inhibition...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
